Paul A Friedman - Chief Executive Officer, Madrigal Pharmaceuticals, Inc

As of November 23, 2018


What is Paul A Friedman's Net Worth?

The current estimated net worth of Madrigal Pharmaceuticals, Inc's Chief Executive Officer, Paul A Friedman, is estimated to be about $230.35M . Paul A Friedman owns about 161,128 units of Madrigal Pharmaceuticals, Inc common stock. In the last 2 years at Madrigal Pharmaceuticals, Inc, Paul A Friedman has sold an estimated value of $21.14M worth.

What is Paul A Friedman's Past Insider Trading?

Paul A Friedman's largest purchase order was 4,000 units , worth over $496K on November 19, 2018. Paul A Friedman's largest sale order was 73,526 units , worth over $21.14M on June 12, 2018. In total, Paul A Friedman has made about 6 transactions over 2 years of their time at Madrigal Pharmaceuticals, Inc. Paul A Friedman usually trades in November and March, with the busiest year in 2018. The most recent transaction was a purchase order of 4,000 units , worth over $471.52K on November 23, 2018.

Ticker
Type
Value
Price per Share
Shares
Filing Date
No matching records found
1

What was Paul A Friedman's Salary in 2020?

As Chief Executive Officer of Madrigal Pharmaceuticals, Inc, Paul A Friedman has a total base salary of $603,500 . Paul A Friedman received compensation valued at about $4,535,446 in 2020 after becoming Chief Executive Officer. The vast majority of their compensation came in the form of option awards of $3,468,500 , other earnings, plans or compensations of $463,446 ,

What is Paul A Friedman's' Mailing Address?

  • Mailing address is C/o Incyte Corporation 1801 Augustine Cut-Off Wilmington DE 19803 DE

Madrigal Pharmaceuticals, Inc Executive Compensation

Name
Year
Salary
Option Awards
Other Earnings Plans or Compensations
Bonus
Other Compensation
Total
Paul A. Friedman, M.D. 2020 $603,500 $3,468,500 $463,446 - - $4,535,446
Paul A. Friedman, M.D. 2019 $584,000 $5,122,000 $387,192 - - $6,093,192
Paul A. Friedman, M.D. 2018 $416,666 $4,907,500 $304,500 - - $5,628,666
Rebecca Taub, M.D. 2020 $490,833 $3,052,280 $339,230 - - $3,882,343
Rebecca Taub, M.D. 2019 $463,948 $4,531,120 $274,775 - - $5,269,843
Rebecca Taub, M.D. 2018 $385,416 $3,729,700 $225,330 - - $4,340,446
Remy Sukhija 2020 $337,500 $2,724,000 $274,680 $100,000 $2,722 $3,438,902
Marc R. Schneebaum 2020 $435,000 $2,219,840 $267,233 - $18,399 $2,940,472
Marc R. Schneebaum 2019 $421,000 $2,868,320 $223,298 - $20,034 $3,532,652
Marc R. Schneebaum 2018 $380,250 $2,748,200 $222,314 - $15,336 $3,366,100
Brian J. Lynch 2020 $425,417 $3,749,840 $260,946 - $11,690 $4,447,893
Brian J. Lynch 2019 $358,602 $3,506,859 $192,602 - $10,574 $4,068,637
No matching records found

Source: https://www.sec.gov/Archives/edgar/data/1157601/000119312521144922/d107927ddef14a.htm

What are Madrigal Pharmaceuticals, Inc's Past Insider Trades?

Madrigal Pharmaceuticals, Inc's most recent insider trade came on August 19, 2020 by Bay City Capital Llc, Bay City Capital Management Iv Llc, Bay City Capital Fund Iv Lp and Bay City Capital Fund Iv Co Invesment Fund Lp who sold 30,000 units worth $3.29M . In the last 3 years, insiders at Madrigal Pharmaceuticals, Inc have sold an estimated value of $446.89M and bought an estimated value of $25.24M worth of shares. Insider trading is most common in June, with the busiest year in 2020. The most active traders at the company are Fred B Craves, Director,  David Milligan, M.D., Director,  and Paul Friedman, Chief Executive Officer .

MADRIGAL PHARMACEUTICALS, INC. Insider Trades

Insider Names
Type
Value
Price per Share
Shares
Filing Date
No matching records found
1